Evifacotrep - ≥99% , CAS No.2413739-88-3

CAS: 2413739-88-3 Cat. No.: E650146 Molecular Weight: 441.77 PubChem CID: 146448026
AVAILABLE TO ORDER
GRADE & PURITY ≥99%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
5mg
E650146-5mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$540.90
10mg
E650146-10mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$810.90
25mg
E650146-25mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$1,710.90
50mg
E650146-50mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$2,700.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

Evifacotrep, a short transient receptor potential channel 5 and 4 ( TRPC5 / TRPC4 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to TRPC5 / TRPC4 with IC 50 s ≤50 nM

In Vitro

Evifacotrep (1 μM; 24 h) inhibits cell growth in ICLN-1694 cells(HEK-TRExhTRPC4). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Evifacotrep (30 mg/kg; sc; once daily or twice daily for 10 days) results in reduced urinary albumin excretion on following injury with puromycinaminonucleoside (PAN) . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:TRPC5

Specifications

Specifications & Purity
≥99%
Biochemical and Physiological Mechanisms
Evifacotrep, a short transient receptor potential channel 5 and 4 ( TRPC5 / TRPC4 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to TRPC5 / TRPC4 with IC 50 s ≤50 nM.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ANTAGONIST
Purity
≥99%
Names and Identifiers
Isomeric SMILES C1CN(CC2=C1C(=NC=N2)OC3=C(C=C(C=C3)F)C(F)(F)F)C4=C(C(=O)NN=C4)Cl
PubChem CID 146448026
Molecular Weight 441.77

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Mechanisms of Action
Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
SolubilityDMSO : 50 mg/mL (113.18 mM; ultrasonic and warming and heat to 60°C)
Molecular Weight441.800 g/mol
XLogP33.100
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count10
Rotatable Bond Count3
Exact Mass441.062 Da
Monoisotopic Mass441.062 Da
Topological Polar Surface Area79.700 Ų
Heavy Atom Count30
Formal Charge0
Complexity734.000
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.